{"title":"肾源性系统性纤维化。","authors":"Irwin M Braverman, Shawn Cowper","doi":"10.3410/M2-84","DOIUrl":null,"url":null,"abstract":"<p><p>Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency. This review discusses recent advances in our understanding of the pathophysiology and clinical approach to patients with chronic kidney disease who require diagnostic imaging with gadolinium-based contrast media.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"2 ","pages":"84"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/a3/medrep-02-84.PMC3026615.pdf","citationCount":"193","resultStr":"{\"title\":\"Nephrogenic systemic fibrosis.\",\"authors\":\"Irwin M Braverman, Shawn Cowper\",\"doi\":\"10.3410/M2-84\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency. This review discusses recent advances in our understanding of the pathophysiology and clinical approach to patients with chronic kidney disease who require diagnostic imaging with gadolinium-based contrast media.</p>\",\"PeriodicalId\":88480,\"journal\":{\"name\":\"F1000 medicine reports\",\"volume\":\"2 \",\"pages\":\"84\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/a3/medrep-02-84.PMC3026615.pdf\",\"citationCount\":\"193\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000 medicine reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3410/M2-84\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000 medicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3410/M2-84","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Nephrogenic systemic fibrosis, initially called nephrogenic fibrosing dermopathy, has been strongly linked to exposure to gadolinium-based contrast media used in magnetic resonance imaging in patients with renal insufficiency. This review discusses recent advances in our understanding of the pathophysiology and clinical approach to patients with chronic kidney disease who require diagnostic imaging with gadolinium-based contrast media.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
